

Bryony Dawkins

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5764112/publications.pdf>

Version: 2024-02-01

19
papers

563
citations

1163117

8
h-index

888059

17
g-index

19
all docs

19
docs citations

19
times ranked

1066
citing authors

#	ARTICLE	IF	CITATIONS
1	Electronic self-reporting of adverse events for patients undergoing cancer treatment: the eRAPID research programme including two RCTs. Programme Grants for Applied Research, 2022, 10, 1-110.	1.0	6
2	Ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory myeloma: MUKeight phase II randomised controlled trial results. Blood Cancer Journal, 2022, 12, 52.	6.2	8
3	Economic evaluation alongside a randomised controlled trial to assess the effectiveness and cost-effectiveness of acupuncture in the management of chemotherapy-induced peripheral neuropathy. Acupuncture in Medicine, 2021, 39, 41-52.	1.0	3
4	Longer-term health and social care strategies for stroke survivors and their carers: the LoTS2Care research programme including cluster feasibility RCT. Programme Grants for Applied Research, 2021, 9, 1-268.	1.0	2
5	Phase III Randomized Controlled Trial of eRAPID: eHealth Intervention During Chemotherapy. Journal of Clinical Oncology, 2021, 39, 734-747.	1.6	127
6	An intervention to increase physical activity in care home residents: results of a cluster-randomised, controlled feasibility trial (the REACH trial). Age and Ageing, 2021, 50, 2063-2078.	1.6	9
7	What factors affect patients' ability to access healthcare? An overview of systematic reviews. Tropical Medicine and International Health, 2021, 26, 1177-1188.	2.3	36
8	Reply to H. Shojima et al. Journal of Clinical Oncology, 2021, 39, 2633-2634.	1.6	2
9	Strategies to enhance routine physical activity in care home residents: the REACH research programme including a cluster feasibility RCT. Programme Grants for Applied Research, 2021, 9, 1-314.	1.0	0
10	The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitor. Trials, 2020, 21, 826.	1.6	3
11	What factors affect patients' access to healthcare? Protocol for an overview of systematic reviews. Systematic Reviews, 2020, 9, 18.	5.3	5
12	Fairer Decisions, Better Health for All: Health Equity and Cost-Effectiveness Analysis. World Scientific Series in Global Healthcare Economics and Public Policy, 2020, , 99-132.	0.1	0
13	Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial. Lancet Oncology, The, 2019, 20, 1760-1772.	10.7	109
14	Cost-Effectiveness of Docetaxel and Paclitaxel for Adjuvant Treatment of Early Breast Cancer: Adaptation of a Model-Based Economic Evaluation From the United Kingdom to South Africa. Value in Health Regional Issues, 2019, 19, 65-74.	1.2	11
15	Prophylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma: the TEAMM RCT. Health Technology Assessment, 2019, 23, 1-94.	2.8	3
16	Distributional cost-effectiveness analysis in low- and middle-income countries: illustrative example of rotavirus vaccination in Ethiopia. Health Policy and Planning, 2018, 33, 456-463.	2.7	25
17	Cost-effectiveness analysis of a multi-dimensional intervention to reduce inappropriate antibiotic prescribing for children with upper respiratory tract infections in China. Tropical Medicine and International Health, 2018, 23, 1092-1100.	2.3	17
18	Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT. Health Technology Assessment, 2018, 22, 1-280.	2.8	16

#	ARTICLE	IF	CITATIONS
19	Using Cost-Effectiveness Analysis to Address Health Equity Concerns. Value in Health, 2017, 20, 206-212.	0.3	181